For more than 40 years ASHP has published the most trusted resource for injectable drug information. Our new ASHP® Injectable Drug Information now delivers the same high-quality content that you can expect from ASHP with even more of the information you need to make decisive patient care decisions.
The 2023 edition of the industry's go-to guide is newly updated with the latest information, the full list of the AHFS® Pharmacologic-Therapeutic Classification© system, multiple new monographs, and nearly 200 new references for a total of over 24,000 total compatibility pairs.
ASHP® Injectable Drug Information™ 2023 features more than 400 monographs, including:
- Brexanolone
- Cefiderocol sulfate tosylate
- Oritavancin
- Oliceridine fumarate
- Remdesivir
- Remimazolam besylate
- Sildenafil citrate
